enVVeno Medical Corporation (NVNO) is a pre-revenue medical device company in clinical-stage development with no approved products and no commercial revenue. Under a liquidation lens as of March 31, 2026, the recovery posture to equity is modestly positive but structurally fragile and rapidly deteriorating. Total assets of $26.1M are dominated by liquid financial instruments: $2.6M in cash and $22.3M in short-term U.S. Treasury securities classified as trading securities at fair value (Level 1). Applying standard liquidation haircuts — 100% on cash, 100% on U.S. government securities (liquid, publicly traded, no credit risk) — recoverable asset value approximates $25.5M on current assets alone, with negligible contribution from non-current assets ($16K net PP&E, $561K operating ROU asset with zero independent liquidation value, $31K security deposit). Total liabilities at face value are $2.35M, consisting of $1.75M in accounts payable and accrued liabilities and $603K in operating lease obligations ($396K current, $207K long-term). The ASC 842 operating lease liability must be treated at face value on liquidation, as early termination of the Irvine, CA facility lease would not extinguish the obligation absent negotiated settlement. Applying this framework yields an estimated liquidation recovery of approximately $23.1M to $23.7M to equity — well above the $247K reported by MFFAIS as CLV/LLV/OLV, which likely reflects market capitalization discounting rather than asset-side calculation. The discrepancy warrants attention: asset-side liquidation value remains meaningfully positive because effectively all assets are cash or near-cash equivalents with no goodwill, no inventory, no receivables, and no intangibles on the balance sheet. The critical risk is the burn rate. Q1 2026 operating cash outflow was $3.2M. Management guides to $4-5M per quarter as the TAVVE pivotal study commences following the April 29, 2026 FDA IDE approval. At $4M/quarter burn with $24.9M in cash and investments, runway extends approximately 6 quarters from March 31, 2026, to roughly Q3 2027, consistent with management's own disclosure. Each quarter of continued operation erodes the liquidation surplus by $3-4M. The company has no debt, no pension obligations, no goodwill, and no intangibles — the balance sheet is unusually clean for a development-stage entity. The 1:35 reverse stock split effected January 20, 2026 reduced shares outstanding from ~22.9M to ~656K and had no economic balance-sheet impact. Post-period, the company raised approximately $0.1M via ATM in April 2026, a de minimis amount. The accumulated deficit stands at $175.2M as of March 31, 2026, up from $171.3M at December 31, 2025, reflecting the $3.85M Q1 net loss.
▼ Community Notes